



ISSN: 2230-9926

Available online at <http://www.journalijdr.com>

IJDR

International Journal of
DEVELOPMENT RESEARCH

International Journal of Development Research
Vol. 5, Issue, 04, pp. 3990-3996, April, 2015

Full Length Research Article

THE EVALUATION OF CANCER INCIDENCE SUSCEPTIBILITY IN THE LIVER OF TYPE 1 AND 2 DIABETIC RATS

¹Fozea Asiri, ¹Ali Alshehri and ^{1,2,*}Abo baker Abdel Shakor

¹Department of Biology, Faculty of Science, King Khalid University, Abha, Saudi Arabia

²Laboratory of Molecular Cell Biology, Department of Zoology, Faculty of Science, Assiut University, Assiut 71516, Egypt

ARTICLE INFO

Article History:

Received 23rd January, 2015
Received in revised form
28th February, 2015
Accepted 16th March, 2015
Published online 29th April, 2015

Key words:

Diabetes,
Cancer,
Apoptosis,
Liver.

ABSTRACT

The relationship between diabetes and cancer development is not clear. But the risk to develop cancer is increased if the person is diabetic. In the present study we induced type 1 and type 2 diabetes in rats by streptozotocin and high fat diet, respectively. Many cell growth and apoptosis related antigens were studied including tumour suppressor antigen; P53, anti-apoptotic protein bcl-2, pro-apoptotic protein bax, cyp1a2 and cyp2e1 and caspase 3. In type 1 and type 2 diabetes cyp2e1, bax, p53 and active caspase 3 were upregulated but active caspase 3 was prominent active in type 1 compared to type 2 diabetes. Both cyp1a2 and bcl-2 were down regulated in both types of diabetes. Bcl-2 was dramatically decreased in type 1 than type 2 diabetes. Normal or high insulin dose treatment could restore the basal line of most parameters but partially restored the level of cyp1a2 and could not restore the level of p53 in type 1 diabetes. High P53 level in both types of diabetes indicates cellular stress and damage. The high level of P53 was accompanied with active caspas3 and reduced bcl-2 in type 1 but not type 2 diabetes.

Copyright © 2015 Fozea Asiri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects of insulin secretion and/or increased cellular resistance to insulin. Type I insulin-dependent diabetes mellitus (IDDM), this form of diabetes represents for only 5-10% of diabetics. IDDM is an autoimmune disease in which the immune system destroys the insulin-making beta cells of the pancreas (Betterle *et al.*, 1984). Non-insulin-dependent diabetes mellitus (NIDDM), referred to as type 2 diabetes. The majority of patients with this form of diabetes are obese, or have an increased percentage of body fat distributed mostly in the abdominal region resulted in insulin resistance (Kissebah *et al.*, 1982; Campbell and Carlson, 1993). Cancer is a group of diseases which characterized by insufficient negative regulation of cell growth. In addition to evasion of cell death, DNA damage and oxidative, mitotic, proteotoxic and metabolic stresses, are also characters of cancer (Hanahan, and Weinberg, 2000; Luo, *et al.*, 2009).

*Corresponding author: Abo baker Abdel Shakor
Laboratory of Molecular Cell Biology, Department of Zoology,
Faculty of Science, Assiut university, Assiut 71516, Egypt

Diabetes and cancer represent two complexes, chronic and possibly fatal diseases. There is a growing body of evidence published in recent years that suggest significant increase in cancer incidence in diabetic patients. It was stated that 8-18% of cancer patients have diabetes (Habib and Rojna, 2013). The worldwide prevalence of diabetes was estimated to rise from 171 million in the year 2000 to 366 million in the year 2030, that may cause the possibility of raising cancer patients as well. Tumor related antigens levels as Bcl-2, CYP 2E1 and CYP 1A2 and cell death/survive related antigens as Bax, P53 and caspase-3 will give good materials for studying the relationship between diabetes and cancer. The caspase family is the largest enzymes involved in apoptosis. They synthesized as proenzymes, and appear distributed in many locations including cytoplasm, nuclear matrix or mitochondrial inter membrane space (Chandra *et al.*, 2001). P53 is a tumor suppressor that is found in modified or functionally inactivated form in human cancers. P53 is activated in response to DNA damage, hypoxia, expression of certain oncogenes and many cytotoxic stimuli. The p53 functions prevent tumor progression by inhibiting the proliferation of damaged or stressed cells through activation of apoptosis, autophagy or senescence (Michalak *et al.*, 2005; Zhivotovsky and Orrenius, 2010).

Bax (Bcl-2-associated X protein) found in mitochondrial membrane and on the inner nuclear membrane but not present on other organelles such as the endoplasmic reticulum (Henshall *et al.*, 2002). Bax is a pro-apoptotic considered important factor in the initiation of cell death pathways (Korsmeyer *et al.*, 2000; von Ahsen *et al.*, 2000) through conformational change and localization to mitochondrial membranes (Gross *et al.*, 1998; Nechushtan *et al.*, 1999). By this way, it promotes release of cytochrome c, the latter can promote caspase activation and initiate apoptosis (Matsuyama and Reed, 2000). Bcl-2 (B-cell lymphoma/leukemia-2 gene) Participates in B-cell malignancies (Tsujimoto *et al.*, 1985). It found on the cytoplasmic face of the mitochondrial outer membrane, endoplasmic reticulum and nuclear envelope (Krajewski, *et al.*, 1993). Bcl-2 prevents programmed cell death through maintaining mitochondrial integrity (Yang *et al.*, 1997; Stanley and Korsmeyer, 1999). The cytochrome P-450 (CYP) represents a super family of hemoproteins that mediate the biotransformation of endogenous and exogenous compounds.

The isoform E1 of the CYP2 subfamily (CYP2E1) is the only member in humans, rats and mice that stimulate the bioactivation of several procarcinogens and involved in drug metabolism (Caro and Cederbaum, 2004; Abdelmegeed, *et al.*, 2005). CYP2E1 has a wide tissue distribution, being highly expressed in the liver but also in many other cell types (Saito, *et al.*, 1997; Yoshinari *et al.*, 2004). CYP1A2 is a constitutive enzyme that is expressed mainly in the liver. It constitutes approximately 13 % of the total hepatic CYP content. This enzyme catalyzes the metabolism of a wide range of chemicals; several of them are suspected human and/or animal carcinogens (Shimada *et al.*, 1994; Hakkola *et al.*, 1998). Taking into consideration the above mentioned information, the main objectives of the current study is to explore the relationship of diabetes and cancer. This will be achieved by studying the levels of different cell death and growth proteins as P53, CYP 2E1, CYP1A2, Bax, Bcl-2 and caspase 3 in liver tissue of two different diabetic rat models. Streptozotocin (type 1) induced diabetes and in high fat diet induced diabetes (type 2).

MATERIALS AND METHODS

Materials

Tween 20, EDTA (ethylene diamine Tetra-acetic acid), EGTA (ethylene glycol Tetra-acetic acid), Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) chemicals, Nitrocellulose membrane, protease inhibitor cocktail, mouse anti-P53 IgG, mouse anti bcl2 IgG, mouse anti bax IgG, mouse anti cyp 2e1 IgG and mouse anti cypla2 IgG were purchased from Sigma (USA). Super Signal West Pico Chemiluminescent Substrate was from Pierce Biotechnology (USA). Mouse anti-caspase 3 IgG, goat anti-mouse IgG-HRP, goat anti- β actin IgG and mouse anti-goat IgG-HRP are from Santa Cruz Biotechnology (USA). Protein Assay Kit was from Bio-Rad (Austria). All other chemicals of good quality -if not mentioned- were obtained from local commercial sources.

Experimental design and animals

Fifty adult male rats weighing 250-300 g obtained from King Khalid University animal house. Suitable temperature of $20 \pm$

4°C and lighting cycle of 12 hours light /dark were also into consideration. All animals were given free access to standard chow and healthy water. All experimental procedures were conducted in strict compliance with the guide of National Institute of Health for the Care and Use of Laboratory Animals. Animal were categorized into 5 groups, each of 10 rats as follow. Control group (cnt) served as normal healthy group. Streptozotocin group (stz) received Streptozotocin 50 mg/Kg one IP injection every day for 5 days and left for 20 days after induction of diabetes. Streptozotocin and normal insulin group (stz +ins) will receive Streptozotocin as group 2 and then 0.75 U/Kg recombinant human insulin for 20 days after induction of diabetes. Streptozotocin and high insulin group (stz +hins) will receive Streptozotocin as group 2 and then 1.3U/Kg recombinant human insulin for 20 days after induction of diabetes. High fat diet group (hfd) will receive 5% of glucose in free access drinking water with high fat rodent chow (46% energy from fat).

Fasting Blood glucose and insulin levels measurements

Rats were fasted overnight and then glucose level was measured from whole tail vein blood with a hand-held glucose test monitor (Lifescan, Johnson and Johnson) and expressed as mg/dl. Serum insulin was quantified using rat insulin ELISA kit (Crystal Chem, USA) according to manufacturer instructions.

Western blot

Liver tissue was lysed in RIPA and grinded by electronic blender for 15 sec. Centrifuge for 20 min (12000 rpm, 4°C). Protein concentration of the supernatant was estimated. Equal protein concentration of each group was loaded with sample buffer and boiled for 5 min to denaturation, then stored at -80°C until use. After SDS-PAGE, transfer of protein bands into nitrocellulose membrane was done by dry blot, blocking of active sites was carried out for 2 hours using 5% skim milk in 1 % TBST. Detection of different tumor related and cell death antigens (P53, P21, P450, Bax and Bcl-2) were carried out by using proper antibodies for each antigen according to manufacturer instructions. Incubation with first Ab overnight was done in closed plastic pages in 1% TBST at 4°C . Secondary Ab HRP conjugated was applied for one hour at room temperature in the same buffer as first Ab. Detection of the specific antigen was carried out by ECL kit. The optical density of each protein was carried out by Image J software and normalized to the corresponding actin band.

Statistical analysis

All data were presented as mean \pm SD. Statistical analyses were performed by using an ANOVA. P value less than 0.05 was considered significant.

RESULTS

Fasting blood glucose and insulin levels

The fasting blood glucose level (fbgl) showed significant increase instz and hfd groups when compared with cnt group (Fig 1A). In contrast, it decreased significantly in stz+ins and

stz+hins groups. This result indicates the incidence of hyperglycemia of stz and hfd groups. Serum insulin was reduced in stz group and restored more or less near the control level in stz+ins (Fig 1B). High insulin treatment caused high serum insulin level, but the highest serum insulin level was obtained from hfd group. The status of serum glucose and insulin levels was summarized in Table 1. The different states of glycemia and insulinemia obtained in this investigation may enable to determine which status is more susceptible for cancer development.

Modulation of CYP 450 in diabetic liver

The detection of two members of CYP 450 belonging to two subfamilies namely; cyp2e1 and cyp1a2 was carried out in different treatments. cyp2e1 (Fig 2A) increased in stz and hfd groups compared to the cnt group, as indicated by densitometric measurements (Fig 2B). The level of cyp2e1 is more or less returned to the basal line of cnt after treatment with insulin in stz+ins and stz+hins groups. CYP1a2 is shown in (Fig 2A).




Fig. 1. Fasting blood glucose and insulin levels in different treatments: fasting blood glucose (fbgl) (A) and insulin levels (B) were estimated as described in method section, data representing the mean \pm SD, * P < 0.05 compared with control

Table 1. Status of glucose and insulin levels in different groups of the experiment

Experimental group	Description
cnt	Normoglycemic and Normoinsulinemic
stz	Hyperglycemic and Hypoinsulinemic
stz + ins	Normoglycemic and Normoinsulinemic
stz + hins	Normoglycemic and Hyperinsulinemic
hfd	Hyperglycemic and Hyperinsulinemic




Fig. 2. Immunodetection of cyp450 subtypes: cyp2e1 and cyp 1a2 were detected by western blot in liver tissues of different treatments (A). Estimation of band optical density was carried out by Image J software and normalized to the corresponding actin band and showing as fold induction (B). Here is a representative figure of at least three independent experiments. Data representing the mean \pm SD, * P < 0.05 compared with control




Fig. 3. Immunodetection of bcl2 and bax: Bcl2 and bax proteins were detected by western blot in liver tissues of different treatments (A). Estimation of band optical density was carried out by Image J software and normalized to the corresponding actin band and showing as fold induction (B). Here is a representative figure of at least three independent experiments. Data are representing the mean \pm SD, * P < 0.05 compared with control




Fig. 4. Immunodetection of P53 and caspase 3: P53 and active caspase 3 were detected by western blot in liver tissues of different treatments (A). Estimation of band optical density was carried out by Image J software and normalized to the corresponding actin band and showing as fold induction (B). Here is a representative figure of at least three independent experiments. Data representing the mean \pm SD, * P < 0.05 compared with control

The level of cyp1a2 decreased in stz, stz+ins, stz+hins and hfd groups compare with cnt group as indicated by densitometric measurements (Fig2B). Notably, the level of cyp1a2 increased little instz+ins when compare with stz group.

Incidence of diabetes modulates bcl-2 and bax proteins in liver

The level of the anti-apoptotic protein bcl-2 decreased sharply in stz group and to a little extent in hfd group (Fig 3 A).Partial restoration of bcl-2 level obtained in stz+ins and stz+hins groups (Fig 3 B).

In contrast, the pro-apoptotic protein bax shown in (Fig 3 A) dramatically increased in stz and hfd groups compared to the cnt group. There is no significant restoration of bax level instz+ins and stz+hins groups (Fig 3 B).

High expression of P53 and induction of apoptosis in diabetic liver

The tumor suppressor antigens P53 reached the highest level in hfd and stz groups (Fig 4 A). Insulin treatment in both normal and high doses did not antagonize the action of diabetes (Fig 4 B). It is well known that P53 may induce

apoptotic cell death under certain cell stress. Accordingly we aimed to measure the activation of the executioner caspase 3. Immunoblot detection of cleaved caspase3 (Fig 4 A) revealed obvious increase in stz group compared with cnt (Fig 4 B). The level of cleaved caspase3 was slightly increased in hfd than cnt group. Treatment with insulin in stz+ins and stz+hins groups resulted in reduction of cleaved caspase3 back to the basal line of cnt.

DISCUSSION

Most of insulin-producing β cells are degenerated or had necrosis upon streptozotocin treatment leading to a decrease in insulin secretion and an increase in blood glucose concentration (Adeyemi *et al.*, 2010). Intracellular action of stz may be according to DNA fragmentation (Morgan *et al.*, 1994) or alkylation (Delaney *et al.*, 1995; Elsner *et al.*, 2000) in pancreatic β cells. In this study, the injection of recombinant human insulin subcutaneously (0.75 U/kg) in stz+ins group and (1.3U/Kg) in stz+hins group daily for 20 days cause decrease in fasting blood glucose levels of stz group. In this case, external insulin use as substitute to original insulin that secreted by β cell after destroyed by stz, this caused significant decrease in blood glucose level. This result is in line with other studies, (Nordquist and Sjöquist, 2009). Significant increase of fasting blood glucose level and high serum insulin was obtained by the administration of oral glucose together with high fat feeding. Feeding of rats on hfd for two weeks was enough to produce insulin resistance syndrome characterized by the increased body weight (obesity), mild hyperglycemia, hypertriglyceridemia, hypercholesterolemia and compensatory hyperinsulinemia (Reaven, 1991). Hyperglycemia resulting from insufficient levels of insulin or its action on cells causes free radicals production which leads to oxidative stress and apoptosis in various cells (Arya, *et al.*, 2011). Apoptosis is regulated by several proteins, the most important one is p53 which normally activated by cellular stress and mediates a growth-suppressive response that involves cell cycle arrest and apoptosis (Kuribayashi and El-Deiry, 2007).

In addition, p53 reduces the expression of anti-apoptotic genes such as bcl2 and up regulates genes promoting apoptosis such as bax (Leri, *et al.*, 1998). Both bcl2 and bax play a main role in regulating apoptosis (Nogueira, *et al.*, 2009). It has been shown that bax can promote caspase activation and initiate apoptosis (Matsuyama and Reed, 2000). There are anti-apoptotic proteins which may be affected by the oxidative stress which produced from hyperglycemia as cyp2e1, cyp1a2 and bcl2. In fact, the increase in cyp2e1 level was previously reported in stz- induced diabetes in rats (Yao *et al.*, 2009; Saravanan and Ponmurugan, 2013) and in hfd-induced insulin resistance (Mantena, *et al.*, 2009). In general, the expression of cyp2e1 is induced by many of endogenous and exogenous compounds including ethanol, acetone, and other low-molecular-weight substrates and by hfd and insulin-deficient diabetes (Schattenberg, *et al.*, 2004; Abdelmegeed, *et al.*, 2005). Low level of cyp1a2 (Pass, *et al.*, 2002) and bcl2 (Hasnan, *et al.*, 2010; Kapoor and Kakkar, 2014) in diabetic animals was recorded. High level of bax in diabetic animals is logic as the reduction of bcl2 level. It indicates the incidence of apoptotic cell death in hyperglycemia.

The up regulation of bax level was also reported in diabetes (Kapoor and Kakkar, 2014) and after feeding with hfd (Wang, *et al.*, 2008). In the current study we observed high level of p53 in stz and hfd groups. It was reported that P53 activation in type 2 diabetes was because of the increase in oxidative stress levels (Goldstein and Rotter, 2012; Yahagi, *et al.*, 2004). We cannot exclude the action of oxidative stress in our study. Furthermore, high glucose-induced oxidative stress causes DNA damage and can stimulate apoptosis via p53-related mechanisms (Allen, *et al.*, 2005). High level of active caspase 3 in the present investigation lined with (Wang, *et al.*, 2008; Kapoor and Kakkar, 2014), they showed increased gene expression of caspase-3 in stz and hfd groups respectively. Our results suggest that the studied cell death and growth antigens were all modified in insulin dependent and independent diabetes. This may increase the possibility of cancer development potential in diabetes.

Conclusion

Both type I and 2 diabetes induces liver damage and modulation of tumor related and apoptotic antigens. More cellular damaged have been occurred in type 1 than type 2 diabetes. Insulin treatment partially rescued these damages. So seeking for modern regimens to controlling blood insulin level in accordance with blood glucose level may be the best solution for avoiding diabetic complications.

Acknowledgment

The authors are indebted to the King Abdulaziz City for Science and Technology (KACST), Saudi Arabia, for financial support of this work (KACST: 34-0256).

REFERENCES

- Abdelmegeed, M.A., Carruthers, N.J., Woodcrof, t K.J., Kim, S.K. and Novak, R.F. 2005. Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes. *Journal of Pharmacology and Experimental Therapeutics*, 315: 203-213.
- Adeyemi, D. O., Komolafe, O. A., Adewole, O. S., Obuotor, E. M., Abiodun, A. A., and Adenowo, T. K. 2010. Histomorphological and morphometric studies of the pancreatic islet cells of diabetic rats treated with extracts of *Annonamuricata*. *Folia morphologica*, 69: 92-100.
- Allen, D. A., Yaqoob, M. M. and Harwood, S. M. 2005. Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. *The Journal of nutritional biochemistry*, 16: 705-713.
- Arya, A. K., Pokharia, D. and Tripathi, K. 2011. Relationship between oxidative stress and apoptotic markers in lymphocytes of diabetic patients with chronic non healing wound. *Diabetes research and clinical practice*, 94: 377-384.
- Betterle, C., Zanette, F., Pedini, B., Presotto, F., Rapp, L. B., Monciotti, C. M. and Rigon, F. 1984. Clinical and subclinical organ-specific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first-degree relatives. *Diabetologia*, 26: 431-436.
- Campbell, P. J. and Carlson, M. G. 1993. Impact of obesity on insulin action in NIDDM. *Diabetes*, 42: 405-410.
- Caro, A. A. and Cederbaum, A. I. 2004. Oxidative stress, toxicology, and pharmacology of cyp2e1. *Annu. Rev. Pharmacol. Toxicol.*, 44: 27-42.

- Chandra, J., Zhivotovsky, B., Zaitsev, S., Juntti-Berggren, L., Berggren, P. O. and Orrenius, S. 2001. Role of apoptosis in pancreatic beta-cell death in diabetes. *Diabetes*, 50(suppl 1), S44.
- Delaney, C. A., Dunger, A., Matteo, M. D., Cunningham, J. M., Green, M. H. and Green, I. C. 1995. Comparison of inhibition of glucose-stimulated insulin secretion in rat islets of Langerhans by streptozotocin and methyl and ethyl nitrosoureas and methanesulphonates: lack of correlation with nitric oxide-releasing or O6-alkylating ability. *Biochemical pharmacology*, 50: 2015-2020.
- Elsner, M., Guldbakke, B., Tiedge, M., Munday, R. and Lenzen, S. 2000. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. *Diabetologia*, 43: 1528-1533.
- Goldstein, I. and Rotter, V. 2012. Regulation of lipid metabolism by p53—fighting two villains with one sword. *Trends in Endocrinology & Metabolism*, 23: 567-575.
- Gross, A., J. Jockel, M. C. Wei and S. J. Korsmeyer. 1998. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. *EMBO J.*, 17:3878–3885.
- Habib, S. L. and Rojna, M. 2013. Diabetes and risk of cancer. *ISRN oncology*, 2013:583786.
- Hakkola, J., Tanaka, E. and Pelkonen, O. 1998. Developmental expression of cytochrome P450 enzymes in human liver. *Pharmacology & toxicology*, 82: 209-217.
- Hanahan, D. and Weinberg, R. A. 2000. The hallmarks of cancer. *cell*, 100: 57-70.
- Hasnan, J., Yusof, M. I., Damitri, T. D., Faridah, A. R., Adenan, A. S. and Norbaini, T. H. 2010. Relationship between apoptotic markers (Bax and Bcl-2) and biochemical markers in type 2 diabetes mellitus. *Singapore Medical Journal*, 51: 50-55.
- Henshall, D. C., Araki, T., Schindler, C. K., Lan, J. Q., Tiekoter, K. L., Taki, W. and Simon, R. P. 2002. Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death. *The Journal of neuroscience*, 22: 8458-8465.
- Kapoor, R. and Kakkar, P. 2014. Naringenin accords hepatoprotection from streptozotocin induced diabetes in vivo by modulating mitochondrial dysfunction and apoptotic signaling cascade. *Toxicology Reports*, 1: 569-581.
- Kissebah A.H., Vydellingum, N., Murray, R., Evans, D.F., Hartz, A.J. and Kalkhoff, R.K. 1982. Relationship of body fat distribution to metabolic complications of obesity. *J Clin Endocrinol Metab*, 54: 254–60.
- Korsmeyer, S.J., Wei, M.C., Saito, M., Weiler, S., Oh, K.J. and Schlesinger, P.H. 2000. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. *Cell Death Differ*, 7:1166–1173.
- Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W. and Reed, J. C. 1993. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. *Cancer Research*, 53: 4701-4714.
- Kuribayashi, K. and El-Deiry, W. S. 2007. Regulation of programmed cell death by the p53 pathway. In *Programmed cell death in cancer progression and therapy*, Springer Netherlands. (pp. 201-221).
- Leri, A., Claudio, P. P., Li, Q., Wang, X., Reiss, K., Wang, S. and Anversa, P. 1998. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. *Journal of Clinical Investigation*, 101: 1326.
- Luo, J., Solimini, N. L. and Elledge, S. J. 2009. Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell*, 136: 823-837.
- Mantena, S., Vaughn, D., Andringa, K., Eccleston, H., King, A., Abrams, G. and Bailey, S. 2009. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. *Biochem. J.*, 417: 183-193.
- Matsuyama, S. and J. C. Reed. 2000. Mitochondria-dependent apoptosis and cellular pH regulation. *Cell Death Differ*, 7:1155–1165.
- Michalak, E., Villunger, A., Erlacher, M. and Strasser, A. 2005. Death squads enlisted by the tumour suppressor p53. *Biochemical and biophysical research communications*, 331: 786-798.
- Morgan, N. G., Cable, H. C., Newcombe, N. R. and Williams, G. T. 1994. Treatment of cultured pancreatic B-cells with streptozotocin induces cell death by apoptosis. *Bioscience reports*, 14: 243-250.
- Nechushtan, A., C. L. Smith, Y. T. Hsu and R. J. Youle. 1999. Conformation of the Bax C-terminus regulates subcellular location and cell death. *EMBO J.*, 18:2330–2341.
- Nogueira, C. V., Lindsten, T., Jamieson, A. M., Case, C. L., Shin, S., Thompson, C. B. and Roy, C. R. 2009. Rapid pathogen-induced apoptosis: a mechanism used by dendritic cells to limit intracellular replication of *Legionella pneumophila*. *PLoS pathogens*, 5: e1000478.
- Nordquist, L. and Sjöquist, M. 2009. Improvement of insulin response in the streptozotocin model of insulin-dependent diabetes mellitus. Insulin response with and without a long-acting insulin treatment. *animal*, 3: 685-689.
- Pass, G. J., Becker, W., Kluge, R., Linnartz, K., Plum, L., Giesen, K. and Joost, H. G. 2002. Effect of Hyperinsulinemia and Type 2 Diabetes-Like Hyperglycemia on Expression of Hepatic Cytochrome P450 and Glutathione S-Transferase Isoforms in a New Zealand Obese-Derived Mouse Backcross Population. *Journal of Pharmacology and Experimental Therapeutics*, 302: 442-450.
- Reaven, G. M. 1991. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension: parallels between human disease and rodent models. *Diabetes Care*, 14: 195-202.
- Saito, H., Ohi, H., Sugata, E., Murayama, N., Fujita, Y. and Higuchi, S. 1997. Purification and Characterization of a Cytochrome P450 from Liver Microsomes of *Xenopus laevis* Archives of biochemistry and biophysics, 345: 56-64.
- Saravanan, G. and Ponmurugan, P. 2013. S-allylcysteine Improves Streptozotocin-Induced Alterations of Blood Glucose, Liver Cytochrome P450 2E1, Plasma Antioxidant System, and Adipocytes Hormones in Diabetic Rats. *International journal of endocrinology and metabolism*, 11:e10927.

- Schattenberg, J. M., Wang, Y., Rigoli, R. M., Koop, D. R. and Czaja, M. J. 2004. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. *Hepatology*, 39: 444-455.
- Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, T.P. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of dmgs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J. Pharmacol. Exp. Ther.*, 270:414-423.
- Stanley, J. and Korsmeyer, 1999. BCL-2 gene family and the regulation of programmed cell death. *Cancer research*, 59(7 Supplement): 1693s-1700s.
- Tsujimoto, Y., J. Cossman, E. Jaffe and C. Croce, 1985. Involvement of the bcl-2 gene in human follicular lymphoma. *Science* (Wash. DC). 228:1440- 1443.
- vonAhsen, O., Renken, C., Perkins, G., Kluck, R.M., Bossy-Wetzl, E. and New meyer, D.D. 2000. Preservation of mitochondrial structure and function after Bid- or Bax-mediated cytochrome c release. *J Cell Biol.*, 150:1027-1036.
- Wang, Y., Ausman, L. M., Russell, R. M., Greenberg, A. S. and Wang, X. D. 2008. Increased Apoptosis in High-Fat Diet-Induced Nonalcoholic Steatohepatitis in Rats Is Associated with c-Jun NH2-Terminal Kinase Activation and Elevated Proapoptotic Bax. *The Journal of nutrition*, 138: 1866-1871.
- Yahagi, N., Shimano, H., Matsuzaka, T., Sekiya, M., Najima, Y., Okazaki, S. and Yamada, N. 2004. p53 involvement in the pathogenesis of fatty liver disease. *Journal of Biological Chemistry*, 279: 20571-20575.
- Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J. and Wang, X. 1997. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. *Science*, 275: 1129-1132.
- Yao, H. T., Lin, P., Chang, Y. W., Chen, C. T., Chiang, M. T., Chang, L. and Yeh, T. K. 2009. Effect of taurine supplementation on cytochrome P450 2E1 and oxidative stress in the liver and kidneys of rats with streptozotocin-induced diabetes. *Food and chemical toxicology*, 47: 1703-1709.
- Yoshinari, K., Sato, T., Okino, N., Sugatani, J. and Miwa, M. 2004. Expression and induction of cytochromes p450 in rat white adipose tissue. *Journal of Pharmacology and Experimental Therapeutics*, 311: 147-154.
- Zhivotovsky, B. and Orrenius, S. 2010. Cell cycle and cell death in disease: past, present and future. *Journal of internal medicine*, 268: 395-409.
